GlassScriptPhysician profile
Stephanie A Rodriguez
NPI 1528651734
$979.83
in general payments reported to CMS, 2019-2025
15 companies · $79.46 in 2025
The $79.46 reported for 2025 was less than what a typical Family provider received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $145 · 2022: $257 · 2023: $195 · 2024: $303 · 2025: $79.46.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $577.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $577.24 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $183.37 | 2021-2025 | Ozempic, Rybelsus |
| Sanofi-Aventis U.S. LLC | $155.86 | 2021-2022 | |
| Amgen INC. | $151.74 | 2023-2025 | Repatha, Otezla, Repatha |
| Bayer Healthcare Pharmaceuticals INC. | $121.82 | 2022-2025 | |
| Lilly USA, LLC | $118.05 | 2021-2024 | Mounjaro, Zepbound |
| Glaxosmithkline, LLC. | $84.34 | 2023-2024 | Arexvy |
| Exact Sciences Corporation | $30.63 | 2023 | Cologuard Collection Kit |
| Cranial Technologies, INC | $25.43 | 2022 | |
| Dysis Medical, INC. | $18.52 | 2022 | |
| Phadia US INC. | $16.68 | 2024 | Immunocap |
| Azurity Pharmaceuticals, INC. | $16.64 | 2024 | Edarbi |
| Pfizer INC. | $15.58 | 2023 | |
| Astrazeneca Pharmaceuticals LP | $14.99 | 2023 | Farxiga |
| Boehringer Ingelheim Pharmaceuticals, INC. | $13.91 | 2023 | Jardiance |
| Merck Sharp & Dohme LLC | $12.27 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Stephanie Rodriguez listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.